World Health Organization Raises Concern Over Severe Scarcity of Weight-Loss Medications
Fewer than a tenth of individuals that would benefit from obesity jabs like Wegovy are able to get them, states the global health agency as it publishes its initial recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for broader and more equitable availability to this class of drugs.
According to forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"The new guidelines affirms that obesity is a lifelong illness that can be managed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant barriers to broad availability to the jabs that can help people shift considerable body mass, says the body.
Weight-Loss Drug Scarcity
Despite the present most favorable scenario, the supply of such drugs might only reach approximately 100 million people – under 10% of eligible patients, as stated by the health organization.
The advice encourages governments and firms to increase access, via approaches including voluntary licensing.
Exclusive production rights on semaglutide – the core component of Novo Nordisk's Wegovy – is due to expire in multiple nations in 2026.
How Obesity Injections Work
The injections imitate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so people consume fewer calories.
Patients commonly start to lose weight within a few weeks of beginning the once-weekly jabs.
Studies indicates people may put most of the weight back on after a year of stopping the drug, because their typical hunger resume.
Being carrying excess weight raises your likelihood for contracting medical conditions, including type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the health agency.
